5/4/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Nevirapin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Nevirapin

Nevirapin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.

  2. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.

  3. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.

  4. Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.

  5. Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.

  6. Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.

  7. Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.

  8. Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.

  9. Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.

  10. Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.

  11. Boehringer Ingelheim. Viramune Produktresumé. EMA [www]. [cited 2025-01-17].

  12. Reprotox. Nevirapin. Micromedex [www]. [cited 2025-01-17].

  13. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19(8):795-9.

  14. Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004;191:985-92.

  15. Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009;23(18):2425-30.

  1. Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.
  2. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.
  3. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.
  4. Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.
  5. Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.
  6. Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.
  7. Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.
  8. Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.
  9. Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.
  10. Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.
  11. Boehringer Ingelheim. Viramune Produktresumé. EMA [www]. [cited 2025-01-17].
  12. Reprotox. Nevirapin. Micromedex [www]. [cited 2025-01-17].
  13. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19(8):795-9.
  14. Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004;191:985-92.
  15. Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009;23(18):2425-30.